Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Overview
Headquarters

5300 Memorial Drive, Suite 950, Houston, TX, 77007, USA

Type of Company

Public

Employees (Worldwide)

15

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML); and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Contact Data
Trying to get in touch with decision makers at Moleculin Biotech, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Executive Vice President & Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer-New Products

Chief Medical Officer, New Products

Director of Clinical Operations

Principal Investigator

Board of Directors

Co-Founder at Moleculin Biotech, Inc.

Former Chief Executive Officer at SICOR, Inc.

Chairman of the Board & Chief Executive Officer at CNS Pharmaceuticals, Inc.

Former Executive Vice President, Chief Commercial Officer at POZEN, Inc.

Director-Energy Programs & Conferences at University of North Texas - Professional Development Institute at G. Brint Ryan College of Business

Paths to Moleculin Biotech, Inc.
Potential Connections via
Relationship Science
You
Moleculin Biotech, Inc.
Owners & Shareholders
Details Hidden

SCM’s objective is to invest capital in a global, healthcare-focused portfolio in order to generate attractive returns for Investors. The firm focuses on selecting individual investments to drive returns. SCM’s long portfolios typically include growth at a reasonable price (GARP) and growth investments when attractive opportunities arise. They look for shorts that are ‘hyped up’ and whose valuations are predicated on expectations that may be unattainable for their short investments.

Details Hidden

SCM’s objective is to invest capital in a global, healthcare-focused portfolio in order to generate attractive returns for Investors. The firm focuses on selecting individual investments to drive returns. SCM’s long portfolios typically include growth at a reasonable price (GARP) and growth investments when attractive opportunities arise. They look for shorts that are ‘hyped up’ and whose valuations are predicated on expectations that may be unattainable for their short investments.

Recent Transactions
Details Hidden

Moleculin Biotech, Inc. issued USD Common Stock

Details Hidden

Moleculin Biotech, Inc. issued USD Units Consisting of Common Stock and Warrants

Details Hidden

Moleculin Biotech, Inc. issued USD Units Consisting of Common Stock and Warrants

Transaction Advisors
Escrow Agent

Advised onMoleculin Biotech, Inc. issued USD Common Stock

Underwriter

Advised onMoleculin Biotech, Inc. issued USD Common Stock

Auditor

Advised onMoleculin Biotech, Inc. issued USD Units Consisting of Common Stock and Warrants

Legal Advisor

Advised onMoleculin Biotech, Inc. issued USD Common Stock

Advisors & Consultants
Publicist

Chief Operating Officer at PCG Advisory Group

Advisor

Former Chief Financial Officer at Moleculin Biotech, Inc.

Advisor

Chief Executive Officer & Founder at The Ruth Group, Inc.

Clients

WPD Pharmaceuticals, Inc. is biotechnology research and development company. The firm focuses on the research and development of medicinal products involving biological compounds and small molecules. Its products include WPD101, Berubicin, WP1066, WP1732, WPD102, WPD103, WP1220, and Annamycin. The company was founded on July 4, 2006 and is headquartered in Vancouver, Canada.

Key Stats and Financials As of 2020
Market Capitalization
$78.5M
Total Enterprise Value
$32.2M
Earnings Per Share
$-1.76
Revenue
$0
TEVNet Income
-1.85x
Debt TEV
0.01x
Net Profit
$-17.4M
Total Debt
$277K
EBITDA
$-19.5M
Total Equity
$17.9M
Suppliers
University of Texas - MD Anderson Cancer Center Schools & Student Services | Houston, TX

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Competitors
Jazz Pharmaceuticals Plc Pharmaceuticals - Dublin, Ireland

• About Us • Mission & Values • Management Team • Board of Directors • Board Committees • Commercial Capabilities • Corporate Responsibility • Ethical Sales & Marketing • Drug Safety & Medical Info • Physician Data Restriction Program • California Compliance Declaration • Stories • What’s in a Name? • Business Development • Locations ABOUT US Jazz Pharmaceuticals plc is an international specialty biopharmaceutical company dedicated to helping patients with unmet medical needs. We identify, develop and commercialize innovative products in focused therapeutic areas, with a strong commercial focus and expertise in narcolepsy, oncology, pain and psychiatry. Our marketed product portfolio includes: XYREM® (sodium oxybate), ERWINAZETM (asparaginase Erwinia chrysanthemi), PRIALT® (ziconotide) solution, intrathecal infusion, FAZACLO® (clozapine, USP) LD and HD , and LUVOX CR® (fluvoxamine maleate). The product information on XYREM, ERWINAZE, PRIALT, FAZACLO LD, FAZACLO HD and LUVOX CR is intended only for residents of the United States. For more information, including complete prescribing information and boxed warnings, click on the product names above. Please visit www.EUSAPharma.com for more information about our international division, EUSA Pharma, and our products marketed outside the U.S. We plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our unique commercial expertise. As we evaluate additional acquisition and in-licensing opportunities, we work closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ unique approach to patient care and patient-focused products may be able to bring a new therapeutic option to the market where none existed previously.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Moleculin Biotech, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Moleculin Biotech, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Moleculin Biotech, Inc..